Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the LentiGlobin BB305 Lentiviral Vector in Subjects With Severe Sickle Cell Disease

NCT02140554 is registered in ClinicalTrials.gov with Genetix Biotherapeutics Inc. as lead sponsor.

NCT NCT02140554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02140554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the LentiGlobin BB305 Lentiviral Vector in Subjects With Severe Sickle Cell Disease
Lead sponsor
Genetix Biotherapeutics Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
February 2, 2015
Completion date
January 30, 2024
Enrollment
54 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease